A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma
Open Access
- 11 September 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (9) , e0183969
Abstract
Autoantibody profiling with a systems medicine approach can help identify critical dysregulated signaling pathways (SPs) in cancers. In this way, immunoglobulins G (IgG) purified from the serum samples of 92 healthy controls, 10 pre-treated (PR) non-Hodgkin lymphoma (NHL) patients, and 20 NHL patients who underwent chemotherapy (PS) were screened with a phage-displayed random peptide library. Protein-protein interaction networks of the PR and PS groups were analyzed and visualized by Gephi. The results indicated AXIN2, SENP2, TOP2A, FZD6, NLK, HDAC2, HDAC1, and EHMT2, in addition to CAMK2A, PLCG1, PLCG2, GRM5, GRIN2B, GRIN2D, CACNA2D3, and SPTAN1 as hubs in 11 and 7 modules of PR and PS networks, respectively. PR- and PS-specific hubs were evaluated in the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome databases. The PR-specific hubs were involved in Wnt SP, signaling by Notch1 in cancer, telomere maintenance, and transcriptional misregulation. In contrast, glutamate receptor SP, Fc receptor-related pathways, growth factors-related SPs, and Wnt SP were statistically significant enriched pathways, based on the pathway analysis of PS hubs. The results revealed that the most PR-specific proteins were associated with events involved in tumor development, while chemotherapy in the PS group was associated with side effects of drugs and/or cancer recurrence. As the findings demonstrated, PR- and PS-specific proteins in this study can be promising therapeutic targets in future studies.Keywords
Funding Information
- Iran National Science Foundation
This publication has 149 references indexed in Scilit:
- BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplificationMolecular Cancer, 2013
- Investigation of Tumor Suppressing Function of CACNA2D3 in Esophageal Squamous Cell CarcinomaPLOS ONE, 2013
- Somatic mutations in the notch, NF‐KB, PIK3CA, and hedgehog pathways in human breast cancersGenes, Chromosomes and Cancer, 2012
- Mast cells and inflammationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Metabotropic glutamate receptors and cancerous growthWiley Interdisciplinary Reviews: Membrane Transport and Signaling, 2011
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) GroupThe Lancet Oncology, 2011
- SUMO-specific protease 2 in Mdm2-mediated regulation of p53Cell Death & Differentiation, 2010
- Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancerEuropean Journal of Cancer, 2009
- Signaling cross-talk between TGF-β/BMP and other pathwaysCell Research, 2008
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007